Delivery Order SPE2DB20D3101-SPE2DB25FRVX1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units) with a ceiling value of $11,578.87. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a non-competitive set-aside arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Lisdexamfetamine 20 mg capsules (100-count units) with a ceiling value of $4,221.50. This competitively awarded, firm fixed-price delivery order is set to be completed by August 8, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Lisdexamfetamine 20 mg capsules (100-count units) under a firm fixed-price contract valued at $11,279.96. This non-competitive delivery order is expected to be completed by September 2, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 30 mg capsules (100-count units) on September 3, 2025, with a ceiling value of $1,176.88 and ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,957.98 to AmerisourceBergen Drug Corp for Lisdexamfetamine 20 mg capsules (100 count) on September 8, 2025, with completion targeted for September 9, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to the vendor's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count) with a ceiling value of $29,095.35. This firm fixed-price, non-set-aside contract is scheduled for completion by September 17, 2025, and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,883.72 for Lisdexamfetamine 30 mg capsules (100-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order under the company's broader pharmaceutical supply arrangements with DLA. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units) with a ceiling value of $1,050.75. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The contract utilizes no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $14,087.04 to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Lisdexamfetamine 70 mg capsules (90-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $2,914.51 to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 60 mg capsules (100 count) on August 19, 2025, with completion expected by August 20, 2025. This firm fixed price, competitively awarded delivery order represents a routine pharmaceutical procurement with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRVX1Delivery Order
The Defense Logistics Agency awarded a $10,066.22 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units). This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and represents a non-competitive set-aside contract. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary pharmaceutical distribution operations. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle valued through December 2026. The IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs globally. Lisdexamfetamine is a prescription stimulant medication commonly used in the treatment of attention deficit hyperactivity disorder, and this order supports the Department of Defense's medical supply requirements for military personnel and healthcare beneficiaries served through the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 9/18/25 |